Evans Blue extravasation Casein kinase 2 Phosphorylated nuclear factor erythroid-2 related factor 2 (Nrf2) Musculo-aponeurotic fibrosarcoma-G Background and purpose: Edema formation, inflammation and increased blood-brain barrier permeability contribute to poor outcomes after intracerebral hemorrhage (ICH). This study examined the therapeutic effect of dimethyl fumarate (DMF), a fumaric acid ester that activates nuclear factor erythroid-2 related factor 2 (Nrf2) and Nrf2 heterodimerization effector protein musculo-aponeurotic fibrosarcoma-G (MAFG) in a murine ICH model. Methods: Male CD-1 mice (n = 176) were subjected to intrastriatal infusion of bacterial collagenase (n = 126), autologous blood (n = 18) or sham surgery (n = 32). Four (4) animals not subjected to ICH (naive) were also included in the study. After ICH, animals either received vehicle, dimethyl fumarate (10 mg or 100 mg/kg) or casein kinase 2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA). Thirty-two mice also received scrambled siRNA or MAFG siRNA 24 h before ICH. Brain water content and neurological function were evaluated. Results: Dimethyl fumarate reduced Evans blue dye extravasation, decreased brain water content, and improved neurological deficits at 24 and 72 h after ICH. Casein kinase 2 inhibitor TBCA and MAFG siRNA prevented the effect of dimethyl fumarate on brain edema and neurological function. After ICH, ICAM-1 levels increased and casein kinase 2 levels decreased. Dimethyl fumarate reduced ICAM-1 but enhanced casein kinase 2 levels. Again, casein kinase 2 inhibitor TBCA and MAFG siRNA abolished the effect of dimethyl fumarate on ICAM-1 and casein kinase 2. Dimethyl fumarate preserved pNrf2 and MAFG expression in the nuclear lysate after ICH and the effect of dimethyl fumarate was abolished by casein kinase 2 inhibitor TBCA and MAFG siRNA. Dimethyl fumarate reduced microglia activation in peri-hematoma areas after ICH. The protective effect of dimethyl fumarate on brain edema and neurological function was also observed in a blood injection mouse model. Conclusion: Dimethyl fumarate ameliorated inflammation, reduced blood-brain barrier permeability, and improved neurological outcomes by casein kinase 2 and Nrf2 signaling pathways after experimental ICH in mice.
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Introduction
Intracerebral hemorrhage (ICH) which accounts for about 15-20% of all deaths from stroke is the rupturing of small blood vessels in the brain parenchyma. Currently, no effective treatment options are available for this fatal stroke subtype, and, even if patients survive the initial injury, a series of secondary events may lead to cerebral edema, progression of neurobehavioral deficits, and possible death (Chen et al., 2014; Ikram et al., 2012; Keep et al., 2012; Pandey and Xi, 2014) .
Evidence from clinical and animal studies suggest that inflammation and oxidative stress which occur after hematoma formation are involved in ICH-induced secondary brain injury and neurological dysfunction (Aronowski and Hall, 2005; Chen et al., 2015) . Vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1), adhesion molecules expressed in the endothelium that are important in inflammation after injury, are increased upon activation of the nuclear factor-κB (NF-κB)-mediated tumor necrosis factor α (TNFα) signaling pathway. TNFα increases early-onset endothelial adhesion by protein kinase C-dependent up-regulation of ICAM-1 expression, which can worsen outcomes following ICH (Javaid et al., 2003; Wang and Doré, 2007) .
Nuclear factor erythroid-2 related factor 2 (Nrf2), a major phase II gene regulator, is a broadly expressed transcription factor that binds Abbreviations: DMF, dimethyl fumarate; MAF-G, musculo-aponeurotic fibrosarcoma-G; Nrf2, nuclear factor erythroid-2 related factor 2; p-Nrf2, phosphorylated nuclear factor erythroid-2 related factor 2; TBCA, (E)-3-(2,3,4,5 tetrabromophenyl)acrylic acid; CK2, casein kinase 2; bICH, blood induced intracerebral hemorrhage; cICH, collagenase induced intracerebral hemorrhage; ICV, intracerebroventricular injection; ICAM-1, intracellular adhesion molecule-1; DAPI, 4′,6-Diamidino-2-phenylindole.
